Filtered By:
Cancer: Leukemia
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 266 results found since Jan 2013.
Clonal Hematopoiesis of Indeterminate Potential Is Associated With Coronary Microvascular Dysfunction In Early Nonobstructive Coronary Artery Disease
CONCLUSIONS: In humans, we observe patients with CMD are more likely to have CHIP, and nearly one-third of major adverse cardiovascular events in CMD are mediated by CH.PMID:36951061 | DOI:10.1161/ATVBAHA.122.318928
Source: Arteriosclerosis, Thrombosis and Vascular Biology - March 23, 2023 Category: Cardiology Authors: Nadia Akhiyat Terra L Lasho Morsaleh Ganji Takumi Toya Chang-Xin Shi Xianfeng Chen Esteban Braggio Ali Ahmad Michel T Corban Keith Stewart Jenna Fernandez Zhuoer Xie Christy Finke Lilach O Lerman Mrinal M Patnaik Amir Lerman Source Type: research
Clonal Hematopoiesis of Indeterminate Potential: Current Understanding and Future Directions
This article summarizes the current knowledge about clonal hematopoiesis of indeterminate potential (CHIP), its association with cardiovascular disease (CVD), and other outcomes, pathogenesis, postulated mechanisms of various pathologies, current knowledge gaps, possible targets of intervention, and therapeutic implications.Recent FindingsRecently, a common age-related hematological entity known as CHIP has been identified as the independent risk factor for CVD. CHIP is defined as the presence of clonally expanded blood cells involving leukemogenic mutations without the evidence of malignancy. CHIP is known to increase the...
Source: Current Oncology Reports - March 16, 2023 Category: Cancer & Oncology Source Type: research
Comparison of Clinical and Molecular Features Between Patients With Essential Thrombocythemia and Early/Prefibrotic Primary Myelofibrosis Presenting With Thrombocytosis in Taiwan
CONCLUSIONS: ET and pre-PMF-T were two distinct disease entities and exhibited different clinical phenotype, genotype, and outcomes.PMID:36857745 | DOI:10.1093/ajcp/aqac173
Source: American Journal of Clinical Pathology - March 1, 2023 Category: Pathology Authors: Ming-Chung Kuo Wen-Yu Chuang Hung Chang Tung-Huei Lin Jin-Hou Wu Tung-Liang Lin Che-Wei Ou Yu-Shin Hung Ting-Yu Huang Ying-Jung Huang Po-Nan Wang Lee-Yung Shih Source Type: research
Non-occupational physical activity and risk of cardiovascular disease, cancer and mortality outcomes: a dose-response meta-analysis of large prospective studies
CONCLUSIONS: Inverse non-linear dose-response associations suggest substantial protection against a range of chronic disease outcomes from small increases in non-occupational physical activity in inactive adults. PROSPERO registration number CRD42018095481.PMID:36854652 | DOI:10.1136/bjsports-2022-105669
Source: British Journal of Sports Medicine - February 28, 2023 Category: Sports Medicine Authors: Leandro Garcia Matthew Pearce Ali Abbas Alexander Mok Tessa Strain Sara Ali Alessio Crippa Paddy C Dempsey Rajna Golubic Paul Kelly Yvonne Laird Eoin McNamara Samuel Moore Thiago Herick de Sa Andrea D Smith Katrien Wijndaele James Woodcock Soren Brage Source Type: research
Neuregulin-1/PI3K signaling effects on oligodendrocyte proliferation, remyelination and behaviors deficit in a male mouse model of ischemic stroke
In this study, we investigated the effect of neuregulin-1 (NRG1) on demyelination and neurological function in an ischemic stroke model, and further explored its neuroprotective mechanisms. Adult male ICR mice underwent photothrombotic ischemia surgery and were injected with NRG1 beginning 30 min after ischemia. Cylinder and grid walking tests were performed to evaluate the forepaw function. In addition, the effect of NRG1 on neuronal damage/death (Cresyl violet, CV), neuronal nuclei (NeuN), nestin, doublecortin (DCX), myelin basic protein (MBP), non-phosphorylated neurofilaments (SMI-32), adenomatous polyposis coli (APC),...
Source: Experimental Neurology - January 23, 2023 Category: Neurology Authors: Mai Yin Cui Yan Qiong Fu Zhuo Li Li Yu Zheng Yi Yu Chan Zhang Yun Qi Zhang Bing Rui Gao Wu Yue Chen Yun-Lyul Lee Moo-Ho Won Min Liao Yong Jian Bai Hui Chen Source Type: research
Scottish Firefighters Occupational Cancer and Disease Mortality Rates: 2000-2020
ConclusionsUK firefighters suffer significant excess mortality from cancer and other diseases when compared with the general population. Preventative health monitoring and presumptive legislation are urgently required to protect UK firefighters ’ health.
Source: Occupational Medicine - January 10, 2023 Category: Respiratory Medicine Source Type: research
Challenging Cases in Cerebrovascular Disease
We present four cases of stroke of uncommon cause and remind clinicians to be open minded to the many possible causes of stroke, in particular because early recognition and treatment is often critical. Case 1 discusses a patient with inflammatory cerebral amyloid angiopathy. The presentation, ability to recur, and current treatment considerations are reviewed. Case 2 discusses microangiopathic thrombotic angiopathy. Diagnosis and treatment are considered. An association with interferon therapy and the evolving terminology of this and related conditions are discussed. Case 3 discusses intracranial hemorrhage secondary to ac...
Source: Seminars in Neurology - January 9, 2023 Category: Neurology Authors: Kelly, Michael A. Singh, Jasmine Balabanov, Alexandra Wadina, Adam Dasovic, Braden Tags: Review Article Source Type: research
Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
